The source of human infertility is to found in the male partner in roughly thirty percent of cases. The urologist, Professor Reza Safarinejad, has shown in a series of studies that using a Ubiquinol-based supplement causes a significant increase in the motility and the number of human spermatozoa. For men with an idiopathic infertility, i.e. with no known cause, he prescribed 200 mg of Ubiquinol to be taken daily for 26 weeks. The end result showed that the seminal fluid had improved significantly. Density increased (+81%), motility improved (+31.7%) as was the morphology of the sperm (+24%) (1).
In earlier studies, Prof. Safarinejad had used Coenzyme Q10 and analysed the qualitative improvement of the seminal fluid (2) as well as the number of pregnancies following such treatment (3). The desire to father a child became a reality for 34.1 per cent of the 287 participants.
Ubiquinol, as the active form of Coenzyme Q10, is more 'bio-available' and more effective with smaller doses. Just like conventional Coenzyme Q10, Ubiquinol ensures a better intracellular energy production and acts as a powerful anti-oxidant as a help in retarding the ageing of cells. Treatment with Ubiquinol has no known side effects. A large number of very thorough studies have proved the effectiveness and harmlessness of this natural micro-nutrient. No medical or surgical operations are required to benefit from this discreet and inexpensive therapy.
(1) Mohammad Reza Safarinejad (et al): Effects of the Reduced Form of Coenzyme Q10 (Ubiquinol) on Semen Parameters in Men with Idiopathic Infertility: a Double-Blind, Placebo Controlled, Randomized Study: The Journal of Urology, Vol. 188, August 2012.
(2) Mohammad Reza Safarinejad (et al): Efﬁcacy of Coenzyme Q10 on semen parameters, sperm function and reproductive hormones in infertile men: The Journal of Urology, Vol. 182, 237-248, July 2009.
(3) Mohammad Reza Safarinejad (et al): The effect of Coenzyme Q10 supplementation on partner pregnancy rate in infertile men with idiopathic oligoasthenoteratozoospermia: an open-label prospective study: Springer Science+Business Media, published online, 13th Nov 2011.